Abstract:Introduction: Liver transplantation (LT) is a life-saving procedure that resolves complications of cirrhosis. However, the metabolic risk factors for nonalcoholic fatty liver disease (NAFLD) persist and potentially worsen in the post-transplant setting, thereby increasing the risk of liver fibrosis. Liver biopsy is the gold standard to diagnose NAFLD and liver fibrosis, but this procedure is invasive and less than ideal for longitudinal monitoring after LT. We aimed to investigate the association of serum steatosis and fibrosis biomarkers with mortality and graft loss in LT recipients. Methods: We included consecutive adults who received a liver transplant at the MUHC in 2014-2021 and were followed up annually. The outcomes measured were death and graft loss, graft loss being defined as graft failure leading to death or re-transplantation. We assessed the prognostic value of the biomarkers ALT, AST, GGT, AST-to-Platelet Ratio Index (APRI), fibrosis-4 index (FIB-4), and hepatic steatosis index (HSI). Hepatic steatosis was defined as HSI >36, and liver fibrosis was characterized as FIB-4 > 3.64 or APRI > 1. Survival analysis and Generalized Estimating Equation (GEE) models were used to assess the association between the biomarkers and the outcomes. Results: Two hundred nineteen patients were followed for 30 months on average. Graft loss and mortality occurred in 12 patients (9%) and 38 (29.5%) resulting in incidence rates of 29.5 (95% CI 20.9-40.6) and 9.6 (95% CI 5-16.8) per 100 person-years, respectively. Patients who died during the follow-up were older, had an older donor, and had a history of diabetes. On multivariable analysis using the GEE model (see Table 1), higher ALT and higher AST were associated with mortality after adjustment for sex, BMI, age, albumin, and platelets. In the time-to-event analysis, the Kaplan Meier curves showed that APRI >1 could be a potential predictor of mortality (P = 0.0729 see Figure 1). Neither FIB-4 (log-rank, P = 0.199) nor HSI (log-rank, P = 0.919) were associated with mortality. None of the biomarkers or liver transaminases were associated with graft loss. Conclusion: Liver transaminases and the serum fibrosis biomarker APRI are associated with mortality in LT recipients. The hepatic steatosis biomarker HSI does not seem to be valuable in predicting outcomes in this population. None among liver transaminases, steatosis or fibrosis biomarkers predicted graft loss. Table 1. - GEE of liver transaminases on death in LT patients Characteristics Univariate Multi-Variate * Odds Ratio 95% CI P-value Odds Ratio 95% CI P-value ALT Moderate/Severe 0.9999 0.9999–1.0000 0.0931 1.0001 1.0000–1.0002 0.0040 AST Moderate/Severe 1.0000 0.9999–1.0000 0.3934 1.0001 1.0000–1.0001 0.0037 ALP Moderate/Severe 0.9999 0.9996–1.0001 0.2807 1.0000 0.9998–1.0001 0.6113 GGT Moderate/Severe 0.9998 0.9996–1.0000 0.0236 0.9998 0.9997–1.0000 0.0596 Smoking status No 1.00 1.00 Yes 0.921 0.71–1.20 0.5444 0.934 0.74–1.18 0.5649 *multivariate models are adjusted for age, sex, albumin, BMI and platelets. Figure 1.: Kaplan-Meier survival curve in LT patients according to the APRI biomarker.

Reversal of graft steatosis after liver transplantation: prospective study.

Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers: A systematic review.

Impact of Graft Steatosis on the Post-transplantation Biliary Complications for Living Donor Liver Transplant Recipients in China

A Clinicopathological Analysis of Liver Retransplantation in 22 Cases

Impact of steatotic liver grafts on early liver function and prognosis of Hver transplantation recipients

Efficacy and Safety of Moderately Steatotic Donor Liver in Transplantation.

The utility of donor liver with steatosis in liver transplantation

Liver Transplantation in 64 Liver Donors with Hepatic Steatosis

Steatotic liver in donor for living related liver transplantation

Prognostic Analysis of Steatosis Donor Liver Transplantation: a Multicenter Clinical Trial

Effect of Steatosis Donor Liver Transplantation on Hepatocellular Carcinoma Recurrence: Experience at A Single Institution

Application of ischaemia-free liver transplantation improves prognosis of patients with steatotic donor livers - a retrospective study

Outcomes of liver transplantation using moderately steatotic liver from donation after cardiac death (DCD)

Clear Mortality Gap Caused by Graft Macrosteatosis in Chinese Patients after Cadaveric Liver Transplantation

Graft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation—A European Registry Study

Application of Fatty Liver in Liver Transplantation

Serum Fibrosis and Steatosis Biomarkers for the Prediction of Mortality in Liver Transplant Recipients

The Effect of Reduced Glutathione and Venous Systemic Oxygen Perfusion on Apoptosis and Ultrastructure of Rat Steatotic Liver Grafts

Systematic Evaluation of the Safety Threshold for Allograft Macrovesicular Steatosis in Cadaveric Liver Transplantation

Donor Liver Steatosis: A Risk Factor for Early New‐onset Diabetes after Liver Transplantation

Body Mass Index Evaluating Donor Hepatic Steatosis in Living Donor Liver Transplantation.